| Literature DB >> 24816923 |
Rune B Jakobsen1, Esben Østrup2, Xiaolan Zhang3, Tarjei S Mikkelsen4, Jan E Brinchmann5.
Abstract
The in vitro process of chondrogenic differentiation of mesenchymal stem cells for tissue engineering has been shown to require three-dimensional culture along with the addition of differentiation factors to the culture medium. In general, this leads to a phenotype lacking some of the cardinal features of native articular chondrocytes and their extracellular matrix. The factors used vary, but regularly include members of the transforming growth factor β superfamily and dexamethasone, sometimes in conjunction with fibroblast growth factor 2 and insulin-like growth factor 1, however the use of soluble factors to induce chondrogenesis has largely been studied on a single factor basis. In the present study we combined a factorial quality-by-design experiment with high-throughput mRNA profiling of a customized chondrogenesis related gene set as a tool to study in vitro chondrogenesis of human bone marrow derived mesenchymal stem cells in alginate. 48 different conditions of transforming growth factor β 1, 2 and 3, bone morphogenetic protein 2, 4 and 6, dexamethasone, insulin-like growth factor 1, fibroblast growth factor 2 and cell seeding density were included in the experiment. The analysis revealed that the best of the tested differentiation cocktails included transforming growth factor β 1 and dexamethasone. Dexamethasone acted in synergy with transforming growth factor β 1 by increasing many chondrogenic markers while directly downregulating expression of the pro-osteogenic gene osteocalcin. However, all factors beneficial to the expression of desirable hyaline cartilage markers also induced undesirable molecules, indicating that perfect chondrogenic differentiation is not achievable with the current differentiation protocols.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24816923 PMCID: PMC4015996 DOI: 10.1371/journal.pone.0096615
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
List of culture supplements.
| Supplements | Working concentration | Company | Catalog number |
| Sodium pyruvate | 1 mM | Gibco (Life Technologies, Carlsbad, CA) | 11360 |
| Ascorbic acid 2-phosphate | 0.1 mM | Sigma-Aldrich (St. Louis, MO) | A8960 |
| Insulin-transferrin-sodium selenite media supplement | 1% | Sigma-Aldrich (St. Louis, MO) | I1884 |
| Human serum albumin | 1,25 mg/mL | Baxter (Deerfield, IL) | N/A |
| Dexamethasone | 100 nM | Sigma-Aldrich (St. Louis, MO) | D4902 |
| Insulin-like growth factor 1 | 100 ng/mL | Sigma-Aldrich (St. Louis, MO) | I3769 |
| Transforming growth factor β 1 | 10 ng/mL | R&D Systems (Minneapolis, MN) | 240-B |
| Transforming growth factor β 2 | 10 ng/mL | R&D Systems (Minneapolis, MN) | 302-B2 |
| Transforming growth factor β 3 | 10 ng/mL | R&D Systems (Minneapolis, MN) | 243-B3 |
| Bone morphogenetic protein 2 | 500 ng/mL | Wyeth (Taplow, UK) | InductOs |
| Bone morphogenetic protein 4 | 500 ng/mL | R&D Systems (Minneapolis, MN) | 314-BP |
| Bone morphogenetic protein 6 | 500 ng/mL | R&D Systems (Minneapolis, MN) | 507-BP |
| Fibroblast growth factor 2 | 10 ng/mL | Sigma-Aldrich (St. Louis, MO) | F0291 |
Figure 1Experimental setup and principal component analysis (PCA).
A. Experimental setup with numbering of the different conditions. When not stated, the cell density was 107 cells per mL. B. PCA on all conditions labelled by days in culture. C. PCA limited to conditions 1–32 on days 0 and 1. D. PCA limited to conditions 1–32 on days 0 and day 7.
Selected wanted and unwanted gene sets.
| Gene symbol | Gene name | Functional role | |
|
|
| aggrecan | Major proteoglycan in hyaline cartilage |
|
| biglycan | Small leucine rich proteoglycans, pericellular location and links to chondroitin sulfate in hyaline cartilage | |
|
| collagen, type XI, alpha1/2 | Fibril forming collagen found associated with type 2 collagen in hyaline cartilage | |
|
| collagen, type II, alpha 1 | The major fibril forming collagen almost exclusively found in hyaline cartilage | |
|
| collagen, type IX, alpha 1/2/3 | Fibril associated collagen with interrupted triple helix found covalently linked to collagen type 2 in hyaline cartilage | |
|
| cartilage oligomeric matrix protein | Prominent component in the ECM of hyaline cartilage possibly stabilizing the collagen fibril assembly and network | |
|
| decorin | Small leucine rich proteoglycan, binds to collagen fibrils and aids in assembly | |
|
| fibromodulin | Small leucine rich proteoglycan, aids in collagen assembly in cartilage in early development | |
|
| hyaluronan and proteoglycan link protein 1 | Abundant protein in cartilage, stabilizes aggregates of hyaluronan and aggrecan | |
|
| lumican | Leucine rich proteoglycan, aids in collagen assembly in cartilage in early development | |
|
| matrilin 3 | Matrix protein restricted to cartilage and binds tightly to aggrecan and/collagen fibrils | |
|
|
| alkaline phosphatase, liver/bone/kidney | Major enzyme leading to mineralization of bone |
|
| collagen type X, alpha 1 | Network forming collagen found predominantly in hypertrophic or diseased cartilage | |
|
| collagen type I, alpha 1/2 | Fibril forming cartilage abundant in bone ECM and virtually absent in hyaline cartilage | |
|
| collagen type III, alpha 1 | Fibril forming collagen often found in mixed fibrils with collagen type 1 | |
|
| osteoglycin | Small leucine rich proteoglycan, induces bone formation | |
|
| peroxisome proliferator-activated receptor gamma | Nuclear receptor, promotes adipogenesis, stimulates lipid uptake and glucose metabolism | |
|
| runt related transcription factor 2 | Transcription factor required for bone formation | |
|
| osterix | Transcription factor essential for osteoblastogenesis | |
|
| osteopontin | Bone protein, potentiates osteoclast adhesion to mineral surfaces | |
|
| versican | Proteoglycan present in fibrous and elastic cartilage, upregulated in dedifferentiating chondrocytes |
Gene symbol and name of all genes comprising the wanted and unwanted marker gene sets. Based on references [28], [38], [66]–[73].
Figure 2Statistical analysis of main effects and interactions at day 7.
A. Normal plot of the standardized effects with the response set to mean expression of wanted markers. B. Corresponding main effects plot of all factors. C and D. Corresponding plots of significant second order interactions. E. Normal plot of the standardized effects with the response set to mean expression of unwanted markers. F. Corresponding main effects plot of all factors. G and H. Corresponding plots of significant second order interactions.
Figure 3Analysis of wanted and unwanted gene expression.
A. Gene sets used to compute mean expression of wanted and unwanted markers. B. Scatter-plot of the mean expression (studentized values) of wanted (x-axis) and unwanted (y-axis) markers at day 0, 1 and 7 of all conditions. C. Scatter-plot of the mean expression (studentized values) of wanted and unwanted markers at day 0 and 7 for condition 1–32.
Gene set enrichment analysis for wanted and unwanted markers.
| False discovery rate | ||
| Condition | Wanted | Unwanted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 15 | <0.0001 | 0.044 |
| 14 | 0.001 | 0.014 |
| 19 | 0.017 | 0.018 |
| 17 | 0.020 | 0.016 |
| 29 | 0.030 | 0.023 |
| 31 | 0.033 | 0.023 |
All conditions enriched for wanted markers are listed and ranked by the false discovery rate for wanted markers (exact FDR values are not stated for FDR <0.0001). Conditions enriched for wanted but not for unwanted markers are marked in bold and stated first.
Figure 4Heatmap of top ranking conditions.
Heatmap of wanted and unwanted genes in all conditions significantly enriched for wanted, but not unwanted markers, color coded by the studentized score.
Figure 5Genes uniformly affected by single factors across conditions 1–32 at day 7.
A. Experimental setup conditions 1–32. B. Heatmap of genes significantly downregulated in all conditions contaning any one of the factors compared to condition 32. C. Heatmap of genes significantly upregulated in all conditions contaning any one of the factors compared to condition 32. Values are log2-transformed mean expressions (n = 3).
Figure 6Genes significantly regulated between key conditions (day 7).
A. Top 20 upregulated and top 20 downregulated genes when adding DEX to TGFB1. B. Top 20 upregulated and top 20 downregulated genes when adding DEX to TGFB1+BMP2. C. All regulated genes when adding BMP2 to TGFB1. D. All regulated genes when adding BMP2 to TGFB1+DEX. Values represent log2 to the fold change between the gene expression in the condition without and the condition with the specified factor added.